Clinical trials: Hematopoietic Cell Transplant
Chronic Graft-versus-host Disease
MSC for Treatment of cGVHD After Allo-HSCT
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
- Trial name
- NCT04692376
- Testing
- Mesenchymal stem cells, Glucocorticoids, cyclosporine
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Nanfang Hospital, Southern Medical University
MDS
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Comparison of survival in patients with or without a matched donor at 36 months
- Trial name
- NCT02757989
- Testing
- transplantation
- Where
- 37 sites in France
- Volunteers
- 79 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Infection
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus.
- Trial name
- NCT00016068
- Testing
- ganciclovir, valganciclovir
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Fred Hutchinson Cancer Center
Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
This is a phase 2, open label, single arm trial. This study aims to assess the efficacy and safety of menin inhibitor BN104 as maintenance therapy in patients with acute leukemia harboring specific genetic alterations who have…
- Conditions
- Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy, Acute Leukemia
- Trial name
- NCT07101497
- Testing
- BN104 monotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation
The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated lesions. There are little data in the literature showing its efficacy in prevention of mucositis in cohorts of patients with…
- Trial name
- STOP MUCITES (NCT02696408)
- Testing
- Laser treatment
- Where
- 3 sites in France
- Volunteers
- 234 people
- Sponsor
- Institut de Cancérologie de la Loire
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Chronic Graft Versus Host Disease
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS. The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC…
- Trial name
- TREG2015001 (NCT02749084)
- Testing
- T reg DLI
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Mario Arpinati
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Normal Donors
Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures
Background: Hematopoietic Stem Cell Transplant (HSCT) represents the second most frequent major organ transplant in the United States.
- Trial name
- NCT01445158
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
The purpose of this study is to evaluate the disease free survival and the overall survival in patients with acute leukemia in first or second complete remission after administrating a CXCR4 antagonist, as a chemo sensitization…
- Trial name
- NCT02605460
- Testing
- Busulfan, Cyclophosphamide, CXCR4 Antagonist
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Oral Mucositis
Low-level Laser Therapy on Inflammatory Mediators During Chemotherapy-induced Oral Mucositis
The aim of the study is to evaluate the effect of low-level laser therapy (LLLT) on the severity of oral mucositis (OM) and inflammatory mediators (pro- and anti-inflammatory cytokines, metalloproteinases and growth factors)…
- Trial name
- LLLTHSCT (NCT02050373)
- Testing
- Low-Level laser
- Volunteers
- 51 people
- Sponsor
- Universidade Federal de Goias
Chronic Myelomonocytic Leukemia (CMML)
Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic…
- Trial name
- NCT07588594
- Testing
- TBF regimen
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Peking University People's Hospital
Pediatric Hematologic Malignancies
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft…
- Trial name
- NCT05011422
- Testing
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT04713956
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU)
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft-versus-Host Disease (GVHD), Hematologic Malignancies
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing…
- Conditions
- Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Trial name
- GVHD-PTCy (NCT06926595)
- Testing
- Cyclophosphamide (primary intervention for GVHD prophylaxis)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
CMV Infection or Reactivation After Allogenic HSCT
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant…
- Trial name
- CMV (NCT06362720)
- Volunteers
- 158 people
- Sponsor
- Siriraj Hospital
Busulfan Pharmacokinetic Analysis, Busulfan Dosing
26DT052; Scaling Busulfan Dose to Body Surface Area in Children
The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-banded dosing table for infants (BSA <0.5 m2) increases the fraction of…
- Conditions
- Busulfan Pharmacokinetic Analysis, Busulfan Dosing, Hematopoietic Stem Cell Transplant (HSCT), Busulfan
- Trial name
- NCT07792369
- Testing
- Busulfan (BU)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Children's Hospital of Philadelphia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.